Novo Holdings and HBM Partners led a $110m Series C round in Numab Therapeutics.

Investment firms Novo Holdings and HBM Partners led a $110m Series C round in Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, with participation from Forbion, Cormorant Asset Management, BVF Partners, RTW Investments, BlackRock and Octagon Capital Advisors. "Backing companies built on clearly differentiated science in areas of major unmet medical need is at the heart of Novo Holdings' investment strategy. We are thus thrilled to co-lead Numab’s Series C financing to support the company at a pivotal stage in growth," Nanna Lüneborg, Novo Partner.